Media headlines about Pulmatrix (NASDAQ:PULM) have been trending somewhat positive on Friday, Accern Sentiment reports. The research group scores the sentiment of press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Pulmatrix earned a news sentiment score of 0.16 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 45.626900210295 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Shares of Pulmatrix (NASDAQ PULM) opened at 1.94 on Friday. The company has a 50-day moving average of $1.87 and a 200-day moving average of $2.59. The stock’s market capitalization is $39.10 million. Pulmatrix has a 52-week low of $0.50 and a 52-week high of $6.98.
Pulmatrix (NASDAQ:PULM) last released its earnings results on Friday, August 4th. The biotechnology company reported ($0.29) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.30) by $0.01. Pulmatrix had a negative net margin of 3,328.91% and a negative return on equity of 152.56%. Equities research analysts anticipate that Pulmatrix will post ($4.13) EPS for the current year.
Pulmatrix Company Profile
Pulmatrix, Inc is a clinical stage biopharmaceutical company developing inhaled therapies to address serious pulmonary disease. The Company’s product pipeline is focused on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with lung disease, including cystic fibrosis.
Receive News & Ratings for Pulmatrix Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Pulmatrix Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.
This post was originally published on *this site*